ALK CEO looks to the allergy products of the future
2014 was a strong year for the Danish allergy group ALK, says CEO Jens Bager. A partnership in Russia with a US-based drug giant should pave the way for new long-term opportunities.
BY BENJAMIN WERNER CHRISTENSEN
With record revenue and the best operating result in the history of the company, 2014 proved to be a great year for the Danish allergy group ALK. CEO Jens Bager is naturally very pleased with the year gone by and especially points to the operating result, which landed on DKK 273 million.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
.jpg)
ALK's adrenaline pen should become growth driver again
For abonnenter
“It’s a very positive development”
For abonnenter
ALK CEO expects favorable price
For abonnenter
